D-Xyrem proved to be too difficult a target to get QD dosing without AM drowsiness. JAZZ has to have that because Flamel's QD drug is advancing. GLPG is in charge of developing the CF drugs thru P2. GLPG's plan is to combine 2 correctors with 1 potentiator for the 508del indication but that is a bit ambitious since none has passed a P1 yet. http://www.glpg.com/index.php/randd/alliances/cystic-fibrosis/
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.